![Lomustine's path from unavailable but cheap to plentiful but expensive Needed: A better manufacturing method](https://cdn.cancerletter.com/media/2019/11/Lomustine-web.jpg)
![Lomustine's path from unavailable but cheap to plentiful but expensive Needed: A better manufacturing method](https://cdn.cancerletter.com/media/2019/11/Lomustine-web.jpg)
Cover Story
Lomustine, a.k.a. CCNU, is an old cancer drug.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
NCI Trials
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
NCI Trials for November 2019
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- Edward Sondik, electrical engineer turned public health expert and one-time interim NCI director, dies at 82
- Trump et al. are wrong: Biden Cancer Initiative is not to be confused with the Beau Biden Cancer Moonshot
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- NCI’s Virtual Clinical Trials Office fills the staffing shortages at cancer centers
- High school science competitions shaped the careers of Regeneron’s co-founders—now, they’re paying it forward
NCI’s Youth Enjoy Science (YES) program also invests in student scientists - How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission